Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06455787 · ClinicalTrials.gov registry record · NA
J-Valve Transfemoral Pivotal Study
A NA study of Aortic Valve Regurgitation and Aortic Valve Disease Mixed, sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences.
- Recruiting
- Registry status
- NA
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT06455787: Recruiting NA study of Aortic Valve Regurgitation and Aortic Valve Disease Mixed, sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences.
NCT06455787 is a NA study of Aortic Valve Regurgitation and Aortic Valve Disease Mixed that is actively recruiting participants, run by JC Medical, Inc., an affiliate of Edwards Lifesciences. The registered enrollment target is 194 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06455787, a NA study of Aortic Valve Regurgitation and Aortic Valve Disease Mixed, is actively recruiting participants, sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR). A Cardiac Magnetic Resonance (CMR) sub-study will examine if intervention for AR translates to improved ventricular remodeling, the impact of LV remodeling on clinical outcomes and quality of life, as well as volumetric and myocardial differences between genders.
Conditions Studied
Interventions
- DEVICE J-Valve Transfemoral (TF) System
Study Locations (20)
California
- Cedars Sinai - Los Angeles
- Stanford University Medical Center - Palo Alto
- Bay Area Structural Heart at Sutter Health - San Francisco
- University of California San Francisco - San Francisco
Georgia
- Emory University Atlanta - Atlanta
- Piedmont - Atlanta
Illinois
- Northwestern University Chicago - Chicago
- Glenbrook - Endeavor Health - Glenview
Louisiana
- Cardiovascular Institute of the South - Houma
- Terrebonne General (CIS) - Houma
Massachusetts
- Massachusetts General Hospital Boston - Boston
- Brigham and Women's Hospital - Boston
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
- CentraCare Heart and Vascular Center - Saint Cloud
Arizona
- HonorHealth Research & Innovation Institute - Scottsdale
Colorado
- UC Health Northern Colorado (Medical Center of the Rockies) - Loveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2032-02 |
| Phase | NA |
What NCT06455787 shows while recruiting
NCT06455787 is an interventional study that assigns participants to a tested intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Aortic Valve Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which J-Valve Transfemoral (TF) System is the first listed.
NCT06455787 names 20 study sites across 12 states, led by California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06455787 about?
NCT06455787 is a clinical study titled "J-Valve Transfemoral Pivotal Study". The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team t...
What is the current status of trial NCT06455787?
This trial is currently recruiting. It is a NA study. The enrollment target is 194 participants. The study started on 2024-10-17. Estimated completion is 2032-02.
What conditions does trial NCT06455787 study?
This clinical trial studies the following conditions: Aortic Valve Regurgitation, Aortic Valve Disease Mixed.
What interventions are being tested in trial NCT06455787?
The interventions under investigation include: J-Valve Transfemoral (TF) System (DEVICE).
Who is sponsoring clinical trial NCT06455787?
This trial is sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06455787 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Valve Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06455787's enrollment target sits among peer trials
194 568th of 2000 higher than 1,433 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
- NCT05351424 · 194 participants · NA
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI